

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6:</b> <b>A61K 9/48</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/01166</b> <b>(43) International Publication Date:</b> <b>12 January 1995 (12.01.95)</b>
<b>(21) International Application Number:</b> <b>PCT/JP94/01043</b>		<b>(81) Designated States:</b> AU, CA, CN, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
<b>(22) International Filing Date:</b> <b>28 June 1994 (28.06.94)</b>		<b>Published</b> <i>With international search report.</i>	
<b>(30) Priority Data:</b> <b>5/160983 30 June 1993 (30.06.93) JP</b>			
<b>(71) Applicant (for all designated States except US):</b> FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP).			
<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HATA, Takehisa [JP/JP]; 2-4-2, Kayougaoka, Nagaokakyō-shi, Kyoto 617 (JP). SHIMOJO, Fumio [JP/JP]; 2-2-13, Daiwahigashi, Kawanishi-shi, Hyogo 666-01 (JP). KADO, Kazutake [JP/JP]; 8-39-303, Asahigaoka, Toyonaka-shi, Osaka 560 (JP). ISHII, Kyoko [JP/JP]; 3-1-9, Uchikyuhojicho, Chuo-ku, Osaka-shi, Osaka 540 (JP). SAWAI, Seiji [JP/JP]; 5-3-104, Yashiro-cho, Takarazuka-shi, Hyogo 665 (JP).			
<b>(74) Agent:</b> SEKI, Hideo; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532 (JP).			

**(54) Title:** ENCAPSULATED MEDICINE

**(57) Abstract**

This invention relates to an encapsulated pharmaceutical dosage form comprising a practically insoluble compound or salt and an intracapsular fluid, and/or a surfactant and/or cellulose derivative. It provides for increased oral absorption as compared with the conventional system because, on release of capsule contents from the capsule shell, the practically insoluble compound or salt undergoes diminution in crystal size.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam

- 1 -

## DESCRIPTION

### ENCAPSULATED MEDICINE

#### 5 TECHNICAL FIELD

This invention relates to an encapsulated pharmaceutical composition comprising a practically insoluble compound or a salt thereof and an intracapsular fluid, and/or a surfactant and/or cellulose derivative and finds 10 application in the medical field.

#### BACKGROUND ART

Being very poorly soluble in water, the so-called practically insoluble compounds are generally absorbed 15 only sparingly on oral administration in a crystalline or finely divided powder form and much research has been undertaken for improving their absorption. As typically disclosed in Japanese Patent Application Kokai H-5-17356, there is known a hard capsule containing a liquid 20 composition comprising nifedipine, which is a practically insoluble compound, polyethylene glycol and polyvinyl-pyrrolidone. In this prior art invention, polyvinyl-pyrrolidone is added for improving the solubility of the drug in water.

25 Heretofore, various absorption-improving agents for practically insoluble compounds have been explored for the purpose of preventing precipitation of such practically insoluble compounds or increasing their solubility in the gastrointestinal tract. However, the technologies so far 30 proposed at times fail to provide for satisfactory improvements in absorption and the advent of new absorption-improving agents for practically insoluble compounds has been awaited.

#### 35 DISCLOSURE OF INVENTION

- 2 -

The inventors of this invention explored a quite new pharmaceutical approach by which the process of precipitation after release of contents of a capsule comprising a practically insoluble compound can be controlled to provide microcrystals in situ and found that a capsule comprising a practically insoluble compound or a salt thereof and an intracapsular fluid, and/or a surfactant and/or cellulose derivative provides for high bioavailability of the compound after oral administration.

5 This invention has been developed on the basis of the above finding.

10

The practically insoluble compound for use in this invention is a compound having an extremely low solubility in water and, as such, showing poorly oral absorption kinetics. As examples of the compound, nilvadipine, 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole, and 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfinylphenyl)pyrazole can be mentioned.

15

20 The intracapsular fluid for use in this invention is a fluid which is conventionally used in soft capsules and, as such, includes polyhydric alcohols such as polyethylene glycol, propylene glycol, butylene glycol, polypropylene glycol, glycerol, polyglycerol, etc. and oils/fats such as fatty acid glycerol esters, sesame oil, soybean oil and so on.

25

Of them, polyhydric alcohols are preferred and polyethylene glycol is more recommendable, and polyethylene glycol 400 is the most advantageous.

30 The surfactant for use in this invention includes nonionic surfactants which are conventionally used in the art. Preferred are polyalcohol ester surfactants and the most useful is polyoxyl stearate.

35 The cellulose derivative for use in this invention includes hydroxypropylcellulose, hydroxypropylmethyl-

cellulose, methylcellulose and carboxymethylcellulose, among other derivatives. Of them, the preferred is hydroxypropylcellulose, the more recommendable is a medium- or low-degree-of-polymerization hydroxypropyl-  
5 cellulose, and the most advantageous is a low-degree-of-polymerization hydroxypropylcellulose.

The pharmaceutical dosage form of this invention may, where necessary, contain those common additives which are conventionally used in pharmaceutical practice (e.g. 10 corrigents, perfumes, etc.). The optimal dosage form is a soft capsule or a hard capsule.

The process for producing the dosage form of this invention employing a practically insoluble compound or a salt thereof and an intracapsular fluid, and/or a 15 surfactant and/or cellulose derivative is now described in detail.

The pharmaceutical dosage form of this invention can be manufactured by mixing a practically insoluble compound or a salt thereof, with an intracapsular fluid, and/or a 20 surfactant and/or cellulose derivative, plus other conventional additives where necessary, and processing the resultant mixture into the desired dosage form in the conventional manner.

By the procedure described above, a pharmaceutical dosage form comprising a practically insoluble compound or a salt thereof and an intracapsular fluid, and/or a 25 surfactant and/or cellulose derivative according to this invention can be provided. For this manufacturing process, the kinds and amounts of intracapsular fluid, 30 surfactant, cellulose derivative and additives can be judiciously selected according to the intended dosage form, the required dose of the practically insoluble compound to be contained and the desired pattern and 35 duration of release of the practically insoluble compound, among other factors.

- 4 -

The preferred formulation according to this invention is the combination of a practically insoluble compound or a salt thereof, an intracapsular fluid and a surfactant, or the combination of a practically insoluble compound or a salt thereof, an intracapsular fluid and a cellulose derivative.

7

The proportions of the respective components of this invention can be judiciously selected according to the designed kinetics of release of the practically insoluble compound. Generally speaking, the preferred proportions based on unity of the practically insoluble compound or salt thereof are about 5 ~ 99.5 for the intracapsular internal fluid, about 0.05 ~ 10 for the surfactant and about 0.05 ~ 20 for the cellulose derivative.

15

The following examples are intended to describe this invention in further detail.

### Example 1

20

A solution of 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole (1.4 g) in PEG-400 (Sanyo Chemical Industries, Ltd., generic name: polyethylene glycol 400) (16.6 g) is mixed with TC-5R (Shin-Etsu Chemical Co., Ltd., generic name: hydroxypropylmethylcellulose) (2.0 g) and the mixture is filled into No. 4 hard capsule shells to provide capsules.

25

The composition per capsule is as follows.

30

### 3-(Difluoromethyl)-1-(4-methoxyphenyl)-5-

14 mq

### (4-methylsulfonylphenyl)pyrazole

PEG-400

166 mg

TC-58

20 mg

- 5 -

Example 2

5 A solution of 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole (1.4 g) in PEG-400 (18.4 g) is mixed with HPC-L (Shin-Etsu Chemical Co., Ltd., generic name: low-degree-of-polymerization hydroxypropylcellulose) (0.2 g) and the mixture is filled into No. 4 hard capsule shells to provide capsules.

10 The composition per capsule is as follows.

10	3-(Difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole	14 mg
	PEG-400	184 mg
	HPC-L	2 mg
15		200 mg

Example 3

20 A solution of 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole (1.4 g) in PEG-400 (17.6 g) is mixed with HPC-L (1.0 g) and the mixture is filled into No. 4 hard capsule shells to provide capsules.

25 The composition per capsule is as follows.

25	3-(Difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole	14 mg
	PEG-400	176 mg
	HPC-L	10 mg
30		200 mg

Example 4

35 The procedure of Example 2 is repeated using MYS-40 (Nikko Chemicals Co., Ltd., generic name: polyoxyl

- 6 -

stearate 40) in lieu of HPC-L to provide capsules.

The composition per capsule is as follows.

5	3-(Difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole	14 mg
	PEG-400	184 mg
	MYS-40	2 mg
<hr/>		
10		200 mg

Example 5

A solution of nilvadipine (5 g) in PEG-400 (85 g) is mixed with HPC-L (10 g) and the mixture is filled into No. 15 4 hard capsule shells to provide capsules.

The composition per capsule is as follows.

20	Nilvadipine	10 mg
	PEG-400	170 mg
	HPC-L	20 mg
<hr/>		
		200 mg

25 [Effect of Invention]

The pharmaceutical dosage form of this invention provides for high bioavailability and sustained action after oral administration because when the capsule contents comprising a practically insoluble compound are released from the capsule, the practically insoluble compound undergoes diminution in crystal size.

To demonstrate the above effect, the results of an in vitro particle size distribution test and an oral absorption test in dogs, both conducted using some representative pharmaceutical compositions according to

this invention are shown below.

Particle size distribution test

(1) Test pharmaceutical compositions

5        Capsule contents 1: Capsule contents of the composition according to Example 1.

10       Capsule contents 2: Capsule contents of the composition according to Example 2.

15       Capsule contents 3: Capsule contents of the composition according to Example 3.

20       Capsule contents 4: Capsule contents of the composition according to Example 4.

25       Capsule contents 5: Capsule contents of the composition according to Example 5.

30       Control capsule contents A: Capsule contents obtained by dissolving 3-(difluoromethyl)-1-(4-methoxy-phenyl)-5-(4-methylsulfonyl-phenyl)pyrazole (70 mg) in PEG-400 (930 mg).

35       Control capsule contents B: Capsule contents obtained by dissolving nilvadipine (50 mg) in PEG-400 (950 mg).

(2) Method

A double-walled glass tube was filled with 10 ml of distilled water and at a constant temperature of 37°C, 0.1 ml of each test capsule contents was added. After 3 hours of stirring, the distribution of solid phase particle size

- 8 -

was determined. The results were expressed in mean particle diameter.

Instrument: Laser light scattering type particle size analyzer LDSA-2300A (Tonichi Computer Applications, Ltd.)

5

Measuring conditions: focus - 100  $\mu\text{m}$

Determined in triplicate

(3) Results

10

	Test capsule contents	Mean particle diameter ( $\mu\text{m}$ )
15	Capsule contents 1	13.7
	Capsule contents 2	8.3
20	Capsule contents 3	6.5
	Capsule contents 4	20.6
	Capsule contents 5	4.6
25	Control capsule contents A	48.2
	Control capsule contents B	34.8

30 The above particle size distribution test made it clear that compared with the capsule contents comprising the practically insoluble compound and intracapsular fluid, the capsule contents comprising the practically insoluble compound and intracapsular fluid, and/or surfactant and/or cellulose derivative give finer crystals on release in water.

35

- 9 -

Since an improvement in oral absorption could be expected from the above results, the following experiment was performed.

5        Oral absorption test

(1)      Test pharmaceutical compositions

The capsule contents 1 ~ 4 and control capsule contents A used in the particle size distribution test were respectively filled into hard capsule shells (referred to as capsules 1 ~ 4 and control capsule A, respectively) and the filled capsules were used in the test.

15        (2)      Method

Using 3 male beagle dogs (body weights 8.5 ~ 10.5 kg) fasted overnight, the above samples were administered to the same dogs at 1-week intervals.

Each composition was filled into hard capsule shells at the ratio of 2 mg/kg of 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole and the filled capsules were administered by the oral route. After administration, the blood was collected serially from the antebrachial vein and the plasma concentration of 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole was determined by HPLC.

25        (3)      Results

The data on maximum plasma concentration ( $C_{max}$ ), area under the plasma concentration-time curve ( $AUC_{0-24}$ ) and bioavailability (BA) after oral administration are shown in the following table. Each value is the mean  $\pm$  standard error.

- 10 -

	Test dosage form	C <sub>max</sub> ( $\mu$ g/ml)	AUC <sub>0-24</sub> ( $\mu$ g $\cdot$ hr/ml)	BA (%)
5	Capsule 1	0.188 ±0.004	0.983 ±0.249	45.0
10	Capsule 2	0.261 ±0.006	1.057 ±0.204	49.1
15	Capsule 3	0.420 ±0.096	1.421 ±0.349	65.6
20	Capsule 4	0.447 ±0.292	1.200 ±0.364	39.5
25	Control capsule A	0.096 ±0.002	0.445 ±0.087	20.7

It is clear from the above oral absorption test data that the pharmaceutical dosage form of this invention is much more orally absorbable than the dosage form comprising only 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole and intracapsular fluid.

The above test results further indicate that unlike the conventional dosage form comprising a practically insoluble compound and an intracapsular fluid intended for preventing precipitation or increasing solubility in the gastrointestinal tract, the capsule of this invention comprising a practically insoluble compound or a salt thereof and an intracapsular fluid, and/or a surfactant and/or cellulose derivative provides for better oral absorption because of the diminution of crystal size in the gastrointestinal tract. Thus, this invention is a very useful oral absorption-improving system for practically insoluble compounds.

## C L A I M S

1. An encapsulated pharmaceutical dosage form characterized by comprising a practically insoluble compound or a salt thereof and an intracapsular fluid, and/or a surfactant and/or cellulose derivative.
2. A pharmaceutical dosage form according to claim 1 comprising a practically insoluble compound or a salt thereof, an intracapsular fluid and a surfactant.
3. A pharmaceutical dosage form according to claim 1 comprising a practically insoluble compound or a salt thereof, an intracapsular fluid and a cellulose derivative.
4. A pharmaceutical dosage form according to claim 2 wherein said intracapsular fluid is a polyhydric alcohol.
5. A pharmaceutical dosage form according to claim 3 wherein said intracapsular fluid is a polyhydric alcohol.
6. A pharmaceutical dosage form according to claim 4 wherein said polyhydric alcohol is polyethylene glycol and said surfactant is polyoxyl stearate.
7. A pharmaceutical dosage form according to claim 5 wherein said polyhydric alcohol is polyethylene glycol and said cellulose derivative is hydroxypropylcellulose.
8. A pharmaceutical dosage form according to claim 7 wherein said polyethylene glycol is polyethylene glycol 400 and said hydroxypropylcellulose is a low-degree-of-polymerization hydroxypropylcellulose.
9. A pharmaceutical dosage form according to claim 8 wherein said practically insoluble compound is nilvadipine, 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole, or 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfinylphenyl)pyrazole.

# INTERNATIONAL SEARCH REPORT

Internat Application No  
PCT/JP 94/01043

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 200 902 (FUJISAWA PHARMACEUTICAL CO., LTD) 12 November 1986 see page 4, line 1 - line 20 see page 5, line 1 - line 15 see example 2 ---	1,3,5 7-9
X	EP,A,0 265 848 (DR. RENTSCHLER ARZNEIMITTEL GMBH) 4 May 1988 see page 4, line 1 - line 7 see page 4, line 11 - line 16 see page 4, line 25 - line 27 ---	1,2,4
X	EP,A,0 278 168 (HARRIS PHARMACEUTICALS LTD.) 17 August 1988 see example 1 see claim 1 -----	1,2,4 7-9

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### \* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

1

Date of the actual completion of the international search

6 September 1994

Date of mailing of the international search report

20.09.94

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentiaan 2  
NL 2280 HV Rijswijk

Authorized officer

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No

PCT/JP 94/01043

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0200902	12-11-86	AU-B-	590255	02-11-89
		AU-A-	5478386	02-10-86
		CA-A-	1275045	09-10-90
		DE-A-	3681755	07-11-91
		JP-A-	61233632	17-10-86
		US-A-	4690822	01-09-87
EP-A-0265848	04-05-88	DE-A-	3636123	05-05-88
		DE-A-	3773327	31-10-91
		JP-A-	63104921	10-05-88
		US-A-	5071642	10-12-91
EP-A-0278168	17-08-88	NONE		

